SOLICITATION NOTICE
A -- Continuous Genotyping services
- Notice Date
- 4/22/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Room 604, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-20040-NG
- Response Due
- 5/7/2002
- Archive Date
- 5/22/2002
- Point of Contact
- Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
holdcram@exchange.nih.gov, rasmusc@mail.nih.gov
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Cancer Prevention Studies Branch (CPSB), plans to procure continuous genotyping services from BioServe Biotechnologies, LTD, 1050 West Street, Laurel Maryland. This procurement will provide for continuation of research studies previously awarded under NCI purchase order 263MQ116056. The North American Industry Classification System code is 541380 and the business size standard is $5M. The Cancer Prevention Studies Branch, Center for Cancer Research, NCI, requires the extraction of high molecular weight DNA from human lymphocyte specimens collected in the Polyp Prevention Trial (PPT). The ultimate purpose of this research project is to obtain high molecular weight DNA from lymphocytes that are suitable for subsequent analyses and to test the quality of the DNA already extracted from some samples. This DNA will then be used in future analyses by many different NCI investigators to investigate the role of different genetic polymorphisms on adenomatous polyp recurrence and diet gene interactions. BioServe is currently in the process of isolating DNA from lymphocytes of 830 polyp prevention trial participants. BioServe Biotechnologies has previously been selected to provide custom high-throughput mass-spectrometry based Matrix Assisted Laser Desorption Ionization Time-of-Flight genotyping services for the PPT. Mass-spectrometry genotyping has provided extremely accurate and reproducible results, with 100% consensus rates in all blinded control samples analyzed. Mass-spectrometry genotyping is also able to genotype polymorphisms where restriction sites are not present. Previously, BioServe has performed XRCC1, APE, MTHFR and GSTm1 assays for the CPSB. BioServe is the only company that does MALDI-TOF of DNA and NCI requires the samples being tested for QC in this Purchase Order, 5000, to be compared to the data from other MALDI data that BioServe is providing. For scientific continuity NCI has a strong programmatic need to continue the work with BioServe to maintain the essential scientific comparability of the data. BioServe is capable of genotyping 10,000 samples in 24 hours with almost 100% reproducibility rate. In addition, they are able to do each genotype assay with as little as 1-3 nano-grams of genomic DNA (other labs are known to use as much as 20-100 nano-grams). To introduce another company would be detrimental to this research work. BioServe Biotechnologies is the only source known to the NCI researcher to obtain high molecular weight DNA from lymphocytes that are suitable for subsequent analyses and to test the quality of the DNA already extracted from samples. BioServe has the expertise in MALDI-TOF techniques which yields 100% reproducibility rate. This notice of intent is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 1:00 PM EST, on May 7, 2002. For further information please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed copies of capability statements will be accepted. If submitting capability statements, please mail one (1) original and two (2) copies to the following address: Please mail to Malinda Holdcraft, NIH/NCI/RCB, 6120 Executive Blvd. Room 6072, Rockville, Maryland, 20852-7194.
- Place of Performance
- Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN00063919-W 20020424/020422213148 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |